關(guān)鍵詞

瑞戈非尼 納武利尤單抗 米吉珠單抗 司庫(kù)奇尤單抗 阿達(dá)木單抗 1型糖尿病 Mpox 納魯索拜單抗 珂羅利單抗

?

#今日行業(yè)熱點(diǎn)#

①The Lancet Oncology：First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial

臨床試驗(yàn)：瑞戈非尼（Regorafenib）聯(lián)合納武利尤單抗（Nivolumab）和化療用于美國(guó)晚期食管癌、胃癌或胃食管結(jié)合部癌:一項(xiàng)單組、單中心、Ⅱ期試驗(yàn)

②The Lancet Rheumatology：Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study

臨床試驗(yàn)：米吉珠單抗（Mirikizumab）對(duì)比司庫(kù)奇尤單抗（Secukinumab）和安慰劑用于中重度斑塊狀銀屑病的安全性和有效性(OASIS-2):一項(xiàng)Ⅲ期、多中心、隨機(jī)、雙盲研究

③The Lancet Rheumatology：Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study

臨床研究：采用多轉(zhuǎn)換研究設(shè)計(jì)評(píng)估阿達(dá)木單抗生物類似藥PF-06410293與阿達(dá)木單抗參考藥的互換性：一項(xiàng)3期、開(kāi)放標(biāo)簽、隨機(jī)、平行組研究

④The Lancet Diabetes and Endocrinology：Maternal type 1 diabetes and relative protection against offspring transmission

綜述：母系1型糖尿病和對(duì)后代傳播的相對(duì)保護(hù)作用

⑤Science Advances：Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study

臨床研究：丹麥淋巴瘤患者大劑量化療和自體造血干細(xì)胞移植后的第二原發(fā)惡性腫瘤:一項(xiàng)基于人群的回顧性隊(duì)列研究

⑥The Lancet Infectious Diseases：Mpox in people with past infection or a complete vaccination course: a global case series

既往感染或完成疫苗接種的人群中的Mpox:全球病例系列

⑦重組全人源抗核因子-κB受體活化因子配體（RANKL）單克隆抗體納魯索拜單抗獲國(guó)家藥監(jiān)局附條件批準(zhǔn)上市，用于骨巨細(xì)胞瘤

⑧基于重組蛋白質(zhì)的新型HBV 免疫治療候選藥物BRII-179聯(lián)合PEG-IFNα用于慢性乙型肝炎的Ⅱ期研究中期取得頂線結(jié)果

⑨GIPR/GLP-1R雙抗多肽偶聯(lián)藥物AMG133用于減重的臨床試驗(yàn)申請(qǐng)獲CDE受理

⑩補(bǔ)體C5抗體珂羅利單抗（Crovalimab）的生物制品許可申請(qǐng)(BLA)獲FDA受理，用于陣發(fā)性睡眠性血紅蛋白尿（PNH）

科學(xué)探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴的合作伙伴！